Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief

Biogen Japan President Takatsugu Den Biogen Japan President Takatsugu Den says that the Alzheimer’s disease (AD)-modifying therapy lecanemab, jointly developed with Eisai and set to score Japan approval this month, will open the door to a new realm in science...read more